VanEck Vectors Biotech ETF (BBH)

140.26 +0.87  +0.62% NASDAQ Dec 10, 16:58 Delayed 2m USD
View Full Chart
Price Chart

Key Stats

Net Asset Value 139.25
Discount or Premium to NAV 0.10%
Turnover Ratio 30.00%
1 Year Fund Level Flows -97.24M

Performance & Returns

  Total Return (Price) Total Return (NAV) Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M 5.99% 6.01% 6.56% 40
3M 15.30% 15.20% 12.68% 22
6M 15.31% 15.21% 11.75% 17
YTD 25.89% 25.08% 22.03% 25
1Y 18.33% 18.19% 14.78% 30
3Y 9.51% 9.49% 14.42% 84
5Y 3.13% 3.11% 7.58% 91
10Y -- -- 14.86% --
15Y -- -- 10.99% --
20Y -- -- 10.34% --
As of Dec. 9, 2019. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash -0.04% 0.00% 0.04%
Stock 100.0% 100.0% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of Dec. 6, 2019

Region Exposure

Americas 93.57%
North America 93.57%
Latin America 0.00%
Greater Europe 2.72%
United Kingdom 0.00%
Europe Developed 2.72%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 3.71%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 3.71%
Market Classification
% Developed Markets 96.29%
% Emerging Markets 3.71%
As of Dec. 6, 2019. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Dec. 6, 2019

Stock Market Capitalization

Giant 11.61%
Large 50.20%
Medium 38.19%
Small 0.00%
Micro 0.00%
As of Dec. 6, 2019

Stock Style Exposure

Large Cap Value 19.17%
Large Cap Blend 27.58%
Large Cap Growth 14.75%
Mid Cap Value 0.00%
Mid Cap Blend 5.50%
Mid Cap Growth 33.00%
Small Cap Value 0.00%
Small Cap Blend 0.00%
Small Cap Growth 0.00%
As of Dec. 6, 2019
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
AMGN Amgen Inc 11.62% 233.79 +0.42%
GILD Gilead Sciences Inc 6.95% 67.07 +0.21%
VRTX Vertex Pharmaceuticals Inc 5.99% 220.32 +0.43%
BIIB Biogen Inc 5.91% 297.25 +0.58%
REGN Regeneron Pharmaceuticals Inc 5.49% 367.24 +0.44%
AGN Allergan PLC 5.26% 185.65 +0.21%
ILMN Illumina Inc 5.23% 328.00 +0.43%
INCY Incyte Corp 5.03% 95.78 +1.04%
IQV IQVIA Holdings Inc 4.59% 146.17 -0.16%
ALXN Alexion Pharmaceuticals Inc 4.37% 111.13 -1.20%
As of Dec. 6, 2019
Advertisement

Basic Info

Investment Strategy
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Large Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Prospectus Objective Specialty - Unaligned
Fund Owner Firm Name VanEck
Benchmark Index
MVIS US Listed Biotech 25 NR USD 100.0%
Reports
One Page Report Download

Manager Info

Name Tenure
Guo Hua (Jason) Jin 1.83 yrs
Hao-Hung (Peter) Liao 7.95 yrs

Net Fund Flows

1M 0.00
3M -18.32M
6M -37.14M
YTD -86.50M
1Y -97.24M
3Y -321.45M
5Y -344.70M
10Y --
As of Nov. 30, 2019

Risk Info

Beta (5Y) 1.371
Max Drawdown (All) 33.76%
Historical Sharpe Ratio (10Y) --
Historical Sortino (All) 1.423
30-Day Rolling Volatility 15.45%
Daily Value at Risk (VaR) 1% (All) 3.73%
Monthly Value at Risk (VaR) 1% (All) 14.71%

Fundamentals

Dividend Yield TTM (12-10-19) 0.39%
30-Day SEC Yield (10-30-15) 0.24%
7-Day SEC Yield --
Weighted Average PE Ratio 23.63
Weighted Average Price to Sales Ratio 6.224
Weighted Average Price to Book Ratio 4.572
Weighted Median ROE 10.58%
Weighted Median ROA 2.62%
Forecasted Dividend Yield 0.75%
Forecasted PE Ratio 17.59
Forecasted Price to Sales Ratio 5.705
Forecasted Price to Book Ratio 4.061
Number of Holdings 25
As of Dec. 9, 2019

Growth Estimates

Forecasted 5 Yr Earnings Growth 9.90%
Forecasted Book Value Growth 7.63%
Forecasted Cash Flow Growth 6.12%
Forecasted Earnings Growth 18.00%
Forecasted Revenue Growth 7.79%
As of Dec. 9, 2019

Comparables

Edit

Attributes

Key Dates
Inception Date 12/20/2011
Termination Date
Last Annual Report Date 9/30/2018
Last Prospectus Date 2/1/2019
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.